Dompé Earns Orphan Drug

Designation for Neurotrophic Keratitis Treatment

| Aug 20, 2014

An Italian-based pharmaceutical company with subsidiaries in New York has been granted orphan drug status for a new drug to treat neurotrophic keratitis, a rare degenerative corneal disease that impacts less than 1 in 5,000 people worldwide.

It can be caused by several different existing conditions, including diabetes, and there are currently no curative treatments available.

The drug – based on recombinant human nerve growth factor, or rhNGF - was developed in Italy at L’Aquila laboratories of the Biopharmaceutical Group, founded on the research of Nobel Prize winner Rita Levi Montalcini, who isolated nerve growth factor in 1952 and continued her research for decades, earning the Nobel Prize in 1986.

Recombinant human nerve growth factor, produced by transferring human genetic material into bacterial DNA, works by enabling the bacteria to produce nerve growth factor that is identical to that naturally produced by the human body, helping to stimulate the growth and maintenance of nerve cells. The cornea is particularly dense with nerves, making it an ideal site for an innovative treatment option.

The FDA and the European Medicines Agency had already assigned rhNGF orphan drug status for the treatment of retinitis pigmentosa, another eye disease without cure that impacts more than one million people worldwide.

The drug is currently in the advanced stages of a double-blind study based in nine European countries involving the treatment of patients suffering from neurotrophic keratitis. More than 170 patients are enrolled in the study, which is designed to evaluate corneal lesion healing, improvement in visual acuity and sensitivity of the cornea.

“We are particularly proud of this new FDA designation, which represents an important recognition of our Research & Development efforts in the field of ophthalmology on a global scale, particularly in North America,” said Eugenio Aringhieri, CEO of the Dompé Group, which focuses on the treatment of rare diseases related to diabetes, organ transplants and oncology. “It is another confirmation of the constant dialogue with the international regulatory agencies in order to bring health issues that still need to be resolved to the forefront as well as possible therapeutic solutions for diseases that are currently without a cure. This is the direction that the efforts of our group is taking, focused on the identification of innovative drugs to protect patients around the world.”

Recumbent human nerve growth factor has also been used to treat peripheral neuropathy.

Click Here To View Or Post Comments

Categories: Diabetes, Diabetes Health, Diabetes Health Magazine, diabetes support, diabetic medicine, Drug, Drugs, medicine, Type 1, Type 1 Diabetes, Type 2, type 2 diabetes

Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12th Annual Product Reference Guide
  • Insulin Syringe Chart
  • Insulin Pen Needles Chart
  • Fast-Acting Glucose
  • Sharps Disposal
  • Blood Glucose Meters Chart
  • Insulin Pumps Chart
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...

Click Here To View Or Post Comments

Comments 0 comments - Aug 20, 2014

©1991-2015 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.